Form 8-K - Current report:
SEC Accession No. 0001628280-24-005333
Filing Date
2024-02-16
Accepted
2024-02-16 16:06:35
Documents
15
Period of Report
2024-02-15
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K frtx-20240215.htm   iXBRL 8-K 30421
5 frtx-20240215_g1.jpg GRAPHIC 29102
  Complete submission text file 0001628280-24-005333.txt   219467

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT frtx-20240215.xsd EX-101.SCH 1905
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT frtx-20240215_lab.xml EX-101.LAB 25156
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT frtx-20240215_pre.xml EX-101.PRE 13052
16 EXTRACTED XBRL INSTANCE DOCUMENT frtx-20240215_htm.xml XML 2544
Mailing Address 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301
Business Address 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301 (720) 505-4755
Fresh Tracks Therapeutics, Inc. (Filer) CIK: 0000819050 (see all company filings)

EIN.: 930948554 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21088 | Film No.: 24648353
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)